Evidence, not endorsement
Protocol library
Regimens are reported in their study or label context. Pages marked sourced are awaiting the owner’s asynchronous editorial review.
| Protocol | Type | Evidence | Status |
|---|---|---|---|
| AOD-9604 A modified growth-hormone fragment investigated for obesity. Human development did not establish an authorised obesity treatment or a routine-use protocol. | Single | Early Human | Sourced |
| Bremelanotide A melanocortin receptor agonist with an authorised US auto-injector for a defined indication. Research-vial calculations are not equivalent to the regulated product. | Single | Regulatory Label | Sourced |
| Cagrilintide A long-acting amylin analogue under clinical investigation for weight management, with dose-ranging human evidence but no routine-use authorisation. | Single | Phase 2 | Sourced |
| Cagrilintide and semaglutide An investigational fixed-ratio combination studied under sponsor-controlled clinical protocols. The research programme does not validate mixing separate consumer vials. | Blend | Phase 2 | Sourced |
| GHK-Cu A copper-binding tripeptide investigated mainly in laboratory, wound and topical cosmetic contexts. Evidence does not establish an injectable human regimen. | Single | Mixed | Sourced |
| Retatrutide A triple GIP, GLP-1 and glucagon receptor agonist in phase 3 development. Explore the published phase 2 research arms and vial-aware calculation examples. | Single | Phase 2 | Sourced |
| Retatrutide and cagrilintide A commonly discussed investigational pairing without a controlled human combination regimen. This page records the evidence gap and does not propose stack quantities. | Stack | Mixed | Sourced |
| Selank A synthetic heptapeptide studied in small human and laboratory studies, with limited internationally accessible clinical evidence and no UK marketing authorisation. | Single | Early Human | Sourced |
| Semaglutide A GLP-1 receptor agonist used in several authorised medicines. Formulation, indication and route are product-specific and must not be treated as interchangeable. | Single | Regulatory Label | Sourced |
| Tesamorelin A growth hormone-releasing factor analogue with an authorised US medicine for a narrow indication. The label does not support general weight-loss or anti-ageing use. | Single | Regulatory Label | Sourced |
| Tirzepatide A GIP and GLP-1 receptor agonist with authorised prescription products. Label regimens apply only to regulated medicines under clinical care. | Single | Regulatory Label | Sourced |